Search

The article discusses a clinical trial, NCT06665035, focusing on the safety and effectiveness of a Tetravalent Dengue Vaccine (TDV) in children under 2 years old. The study aims to evaluate the vaccine's immunogenicity and safety by administering two doses of TDV or a placebo to children aged 6-21 months. Blood samples will be collected to assess the vaccine's impact on the immune system, with participants visiting the clinic 8 times for vaccinations, blood draws, and health checks. The trial is set to conclude on March 3, 2030, with detailed outcome measures and eligibility criteria provided. [Extracted from the article]

The article discusses the development of a thymidine kinase-expressing yellow fever 17D reporter virus that can be used to track viral replication and tissue tropism in live-attenuated vaccines like yellow fever 17D. This reporter virus can convert nucleoside analogues to induce cell death or be used for bioorthogonal labeling of infected cells. The study shows that the 17D-TK virus can be used in combination with radiolabeled tracers for real-time detection and localization of active viral replication sites in living animals using positron emission tomography (PET). [Extracted from the article]

Researchers at the University of Iowa conducted a study on the immune modulation induced by the live attenuated yellow fever vaccine. They found that the vaccine reduced T-cell receptor signaling, potentially influencing clinical outcomes. The study, supported by various organizations including the US Department of Veterans Affairs and NIH, aimed to understand the off-target effects of live vaccines and their impact on immune functions. This research, published in The Journal of Infectious Diseases, sheds light on the mechanisms behind the beneficial effects of live vaccines and their implications for vaccination strategies. [Extracted from the article]

A recent study conducted by researchers at Kansas State University has developed and evaluated two rapid lateral flow assays (LFAs) for the on-site detection of African Swine Fever Virus (ASFV). ASF is a highly contagious and lethal transboundary animal disease, and early detection is crucial for control. The LFAs, which use immunogenic antigens of ASFV, showed high sensitivity and specificity and delivered results in just 15 minutes. These LFAs have the potential to be user-friendly and field-deployable tools for ASF control, particularly in areas with limited laboratory resources. [Extracted from the article]

A recent study conducted by researchers at the Lebanese American University has focused on the Colorado tick fever virus, a medically significant tick-borne virus that is mainly found in the western parts of the United States and southwest Canada. The study aimed to develop a potential vaccine against this virus by identifying epitopes within two critical proteins and using reverse vaccinology and computational techniques. The researchers created a multi-epitope subunit vaccine that showed efficacy and immunogenic response during immune simulation. This research provides valuable insights into the treatment and prevention of infections caused by the Colorado tick fever virus. [Extracted from the article]

A new report discusses research findings on African swine fever (ASF), an emerging disease caused by the African swine fever virus (ASFV) that poses a significant threat to the global swine industry. The study evaluated the deletion of the A137R gene in the ASFV virulent Stavropol_01/08 strain and found that it did not fully attenuate the strain. The researchers also identified the p11.5 protein as a potential serological DIVA marker for an attenuated ASF vaccine. This information may be useful for those studying ASF and working towards the development of safe vaccines. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the signaling mechanisms that drive the immune response in infected cells following the yellow fever virus 17D (YFV-17D) live attenuated vaccine. The study found that YFV-17D uniquely induces mitochondrial hyperactivity, generating reactive oxygen species (mROS) and peroxynitrite, which are critical messengers for activating innate immunity. This metabolic stress and innate immune response are linked to drive type I IFN expression, which is essential for vaccine effectiveness. The research provides a molecular understanding of the vaccine's antiviral immunity. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

A new study conducted by researchers at Southwest Forestry University in Kunming, China, explores the immunogenicity and protective efficacy of aerosolized live-attenuated Yellow Fever 17D vaccine in mice. The study found that aerosolized administration of the vaccine induced robust immune responses in mice, including the production of specific secretory IgA in bronchoalveolar lavage. Additionally, all immunized animals survived a lethal dose of Yellow Fever virus challenge. These findings support further development of aerosolized Yellow Fever 17D vaccine in the future. [Extracted from the article]

A new report published by a researcher at the Food and Agriculture Organization of the United Nations discusses the challenges in applying African Swine Fever (ASF) vaccines in Asia. The report emphasizes the importance of quality vaccines in managing ASF, which poses a significant threat to the pork industry in Asia. It highlights the risks associated with substandard vaccines and calls for rigorous testing and regulations to ensure vaccine effectiveness and safety. The report also advocates for the implementation of vaccines that differentiate infected from vaccinated animals (DIVA) to enhance disease management strategies. Overall, the report underscores the need for stringent standards in vaccine development and adherence to regulatory guidelines to successfully manage ASF and maintain public trust in vaccines. [Extracted from the article]

A new study from Henan Agricultural University in China focuses on African swine fever (ASFV), a complex DNA virus that causes a disease in pigs. The researchers aimed to identify a potential protective antigen against ASFV infection by characterizing the epitope of a specific protein called pB125R. They produced monoclonal antibodies against pB125R and identified a conserved epitope that could be used in the development of an epitope-based vaccine. The study provides a foundation for further research and the development of vaccines against ASFV. [Extracted from the article]

A new report from the China Institute of Veterinary Drug Control discusses the African swine fever virus (ASFV), a highly contagious pathogen that causes a severe infectious disease in pigs. The virus is characterized by a complex structure and various immunosuppression proteins, making it difficult to develop effective vaccines or treatments. The report summarizes the interaction between ASFV and the host immune system, as well as the involvement of virulence-related genes and proteins. The aim is to provide a better understanding of how ASFV impacts the host and to develop a rational insight into the development of a vaccine. [Extracted from the article]

A recent study analyzed the immune response of individuals who received the yellow fever vaccine. The researchers found that there was a temporary increase in the expression of interferon-stimulated genes (ISGs) in dendritic cells and monocytes, which are types of immune cells. This activation state correlated with the early production of protective antibodies. The study also identified a specific marker, SIGLEC1/CD169, that could indicate this activation state. This research provides insights into the early immune response to yellow fever vaccination and may have implications for understanding other RNA virus infections. [Extracted from the article]

A new study conducted by researchers at South China Agricultural University focuses on the African swine fever virus (ASFV), a highly fatal infectious disease in pigs. The study highlights the importance of early detection in preventing and controlling ASF, as there is currently no effective vaccine or targeted therapeutic medication available. The researchers successfully obtained monoclonal antibodies (mAbs) against the ASFV E165R protein, which is highly expressed in the early stages of infection. They also identified two novel linear B cell epitopes that are highly conserved in different genotypes of ASFV, providing valuable information for the development of immunodiagnostic reagents. [Extracted from the article]

A meta-analysis conducted by researchers at the University of Ferrara in Italy evaluated the immunogenicity, safety, and efficacy of the TAK-003 dengue vaccine. The study included data from 19 trials with over 20,000 participants. The results showed that the vaccine had an excellent safety profile and demonstrated high immunogenicity against all four dengue virus serotypes after two doses. The two-dose immunization course was found to reduce the risk of virologically confirmed dengue fever in seropositive children/adolescents, while a single dose showed a high immunogenic response in both adults and children/adolescents. The study supports the use of TAK-003 for preventing dengue fever in endemic countries, but uncertainties remain regarding its use in non-endemic countries. [Extracted from the article]

Researchers at the Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences have identified two linear epitopes on the MGF_110-13L protein of the African swine fever virus (ASFV). The study aimed to explore ASFV antigenic proteins to aid in vaccine development and serodiagnostic target identification. The researchers generated two monoclonal antibodies against MGF_110-13L and mapped their epitopes using enzyme-linked immunosorbent assay (ELISA) and Western blot techniques. The findings provide valuable information on the antigenic epitopes of the MGF_110-13L protein and suggest its potential as a target for detecting ASFV antibodies. This research contributes to the understanding and control of African swine fever, a highly contagious and deadly swine disease. [Extracted from the article]

Researchers from the Chinese Academy of Agricultural Sciences have conducted a study on the African Swine Fever Virus (ASFV) and its immunogenicity. They focused on the C129R protein of ASFV and developed a recombinant adenovirus vaccine using this protein. The study found that the vaccine demonstrated strong immunogenicity and enhanced both humoral and cellular immunity in immunized mice. Additionally, the researchers identified four potential T-cell epitopes in the C129R protein. These findings provide a foundation for further exploration of ASFV and the development of novel ASF vaccines. [Extracted from the article]

A recent study conducted at Cornell University focused on the African Swine Fever Virus (ASFV), a large dsDNA virus with over 150 proteins. The researchers aimed to identify immunodominant B-cell epitopes in the ASFV p30 protein and evaluate the immunogenicity of recombinant viruses expressing ASFV genes. They found that antibodies elicited against ASFV p30 exhibited antibody-dependent cellular cytotoxicity (ADCC) activity. These findings contribute to our understanding of the immune response to ASFV and highlight the importance of the p30 protein as a target for antibody responses. [Extracted from the article]

Researchers from Kasetsart University in Bangkok, Thailand have conducted a study to improve the solubility, yield, and purity of recombinant p30, a protein associated with African swine fever virus (ASFV). They achieved this by tagging the p30 protein with a small ubiquitin-like modifier (SUMO) and modifying the protein purification process. The study found that the solubility and expression levels of the SUMO-tagged p30 were significantly enhanced compared to the untagged p30. The modified purification process also increased the yield of purified p30. These findings have implications for the production of other recombinant proteins and could be used in immunization and diagnostic purposes. [Extracted from the article]

Researchers from the Beijing Institute of Pharmacology and Toxicology have published a study on the African Swine Fever Virus (ASFV). The study focuses on the development of monoclonal antibodies (mAbs) that target the CD2v protein of ASFV. The researchers successfully identified optimal antibody pairs for a highly sensitive sandwich ELISA and characterized the antigenic structures recognized by the mAbs. The study concludes that the mAbs obtained in this research have potential for use in ASF diagnostic strategies and may contribute to vaccine development against ASFV. [Extracted from the article]

A clinical trial, NCT06388785, has been launched in Malaysia to monitor the adverse events following immunization with the QDENGA vaccine. The study aims to collect data on the number and type of medical problems (adverse events) experienced by individuals who have already been vaccinated with QDENGA. The study also aims to collect data on the number of vaccinated individuals who require hospitalization due to severe dengue fever. The trial is observational and will not involve any additional vaccinations. The study is expected to be completed by September 2027. [Extracted from the article]

A patent application has been published by the US Patent and Trademark Office for a live attenuated dengue vaccine. The application, filed by Merck Sharp & Dohme LLC, describes different formulations of the vaccine that aim to improve stability and yield after drying. The formulations include various ingredients such as cellulose derivatives, sugar alcohols or glycols, and buffers. The goal of this invention is to develop a stable and effective vaccine against dengue virus. [Extracted from the article]

A recent study conducted by researchers at Huazhong Agricultural University in Wuhan, China, has explored the potential of using Saccharomyces cerevisiae (SC) for oral immunization against the African swine fever virus (ASFV). ASFV is a highly complex virus that poses a significant threat to the global swine industry. Currently, there are no commercial vaccines available for ASFV, except in Vietnam. The study found that the recombinant SC strains containing multiple ASFV antigens induced strong immune responses in mice, suggesting that this oral immunization strategy could be a promising approach for developing a vaccine against ASFV. Further research is needed to evaluate its efficacy in swine. [Extracted from the article]

A recent study conducted by Mahidol University explored the impact of prior yellow fever (YF) or Japanese encephalitis (JE) vaccination on the efficacy of Takeda's dengue vaccine candidate, TAK-003. The study found that TAK-003 was well-tolerated and efficacious in different epidemiological settings, with no clinically relevant impact of prior JE or YF vaccination on its performance. Vaccine efficacy was 55.7% for those with YF vaccination, 77.8% for JE vaccination, and 53.5% for no prior YF/JE vaccination. The study concluded that TAK-003 is a safe and effective vaccine for children. [Extracted from the article]

Researchers from The University of Adelaide have submitted a patent application for a Zika virus vaccine. The vaccine utilizes a non-structural protein of the Zika virus, NS1, which has been found to elicit a protective immune response in mammals. By linking the NS1 protein to a signaling peptide that facilitates secretion from mammalian cells, the vaccine aims to prevent or minimize Zika virus infection, particularly in pregnant women and their partners. The patent application provides detailed information on the composition, administration methods, and potential therapeutic applications of the vaccine. [Extracted from the article]

A recent study conducted by the National Biotechnology Development Agency in Abuja, Nigeria, has developed a multiepitope vaccine candidate for the African swine fever virus. The researchers analyzed protein sequences from 42 strains of the virus and identified immunodominant epitopes. These epitopes were then evaluated for their antigenicity, immunogenicity, allergenicity, and toxicity. The resulting vaccine candidate showed promising properties, such as hydrophilicity, non-allergenicity, and immunogenicity. Further testing is needed to determine its safety and efficacy. [Extracted from the article]

According to a preprint abstract, a dynamic, stochastic model of yellow fever (YF) transmission was developed to estimate the burden of the disease and inform vaccination strategies. The model used environmental factors to estimate the force of infection and the basic reproduction number for human-to-human transmission. The study found that the current vaccination coverage target is sufficient to reduce the effective reproduction number below 1 in most regions of Africa, but not low enough to eliminate outbreaks in areas with high seasonal variation. However, coverage levels aligned with future targets are expected to significantly decrease the proportion of regions with high transmission. This research has not yet undergone peer review. [Extracted from the article]

Takeda Vaccines Inc. has been issued a patent for compositions and methods related to dengue virus chimeric constructions in vaccines. Dengue fever, caused by infection with dengue virus, can have severe consequences and currently has no effective vaccine or drug treatment. The patent describes chimeric dengue virus constructs that can be used in immunogenic compositions to induce an immune response against one or more dengue virus serotypes. These constructs can be generated and passaged in vitro and used in a vaccine or immunogenic composition. The patent also mentions the possibility of combining these compositions with other immunogenic compositions against other flaviviruses. For more detailed information, readers can refer to the full patent. [Extracted from the article]

CureVac SE has been issued a patent for a flavivirus vaccine that targets yellow fever virus and dengue virus. Flaviviruses are RNA arboviruses that cause diseases like yellow fever and dengue fever. The patent aims to develop a safe and effective vaccine that provides long-lasting immunity against all four serotypes of dengue virus. The invention focuses on creating immunogenic compositions that can be used for prevention or treatment, are stable without refrigeration, and can be produced quickly and affordably. The patent claims a pharmaceutical formulation containing RNA in a lipid nanoparticle, which encodes proteins from dengue virus and yellow fever virus. It also includes a method for treating or inhibiting dengue virus infection using this formulation. [Extracted from the article]

A study conducted at La Paz University Hospital in Madrid, Spain, examined the off-label vaccination of yellow fever (YF) and hepatitis A (HA) in traveling children. The researchers aimed to assess the adverse effects associated with off-label vaccination and expand the vaccine spectrum for pediatric populations. The study found that there were no immediate adverse effects reported, and mild common adverse effects such as diarrhea, fever, or malaise were experienced by 10.8% of patients within 10 days after vaccination. The research suggests that off-label vaccination for YF and HA could be considered safe. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the development of a forecasting model called GeoSeeq Dengue, which predicts dengue fever outbreaks in Brazil. The model accurately predicts outbreaks up to 6 months in advance and can be used to inform public health responses, such as vector control programs and public health education messaging. The researchers also explore how the model could be adapted for use in other countries. This research has not yet undergone peer review. [Extracted from the article]

A recent study aimed to develop a multi-epitope vaccine candidate against Kyasanur Forest Disease Virus (KFDV), a tick-borne viral zoonosis. The researchers used immunoinformatic tools to analyze KFDV genome sequences and identify prioritized B and T cell epitopes. These epitopes were then combined to construct the vaccine candidate, which showed stable interaction with the TLR2-TLR6 receptor complex. However, further experimental validation is needed to confirm the effectiveness and safety of the vaccine candidate. [Extracted from the article]

A recent report from the University of Nebraska-Lincoln discusses the progress made in developing gene-deleted live-attenuated African swine fever virus vaccines. African Swine Fever (ASF) is a highly lethal viral disease in swine, causing significant economic losses and impacting global food security. Live-attenuated virus vaccines that remove virulence genes have shown promise in terms of safety and efficacy. This article summarizes the recent advancements in generating and characterizing these gene-deleted vaccine candidates. The research was supported by the United States Department of Agriculture and the University of Nebraska-Lincoln Agricultural Research Division. [Extracted from the article]

A recent study conducted by the Instituto Rene Rachou has examined the immune response induced by standard and fractional doses of the 17DD yellow fever vaccine. The research found that both doses of the vaccine were effective in inducing viremia, antibodies, and soluble markers early after immunization. However, the fractional dose led to a sustained expansion of helper T-cells and a more complex network involving follicular helper T-cells and B-cells compared to the standard dose. The study concludes that the fractional dose can replace the standard dose in inducing a robust immune response against yellow fever. [Extracted from the article]

A new report from the University of Milano Bicocca provides valuable information on the humoral response to primary yellow fever (YF) vaccination in infants and children. The study reviewed 33 articles on the humoral response to YF vaccination in children aged 12 years or younger. The findings indicate that primary YF vaccination effectively provides humoral immunity in the pediatric population, with a vaccine response rate of 91.9% within three months following vaccination. However, the humoral response declines over time, and a differential response was observed based on the vaccine substrain. This research has important implications for future policies and further research on YF vaccination in infants and children. [Extracted from the article]

Takeda, a pharmaceutical company, has partnered with Biological E. Limited, a vaccines and biologics company in India, to manufacture Takeda's dengue vaccine, TAK-003. This partnership aims to combat the global public health threat of dengue fever and aligns with the World Health Organization's goal of achieving zero case-fatality rate due to dengue by 2030. The partnership will enhance manufacturing capabilities, potentially reaching 50 million doses annually and accelerating Takeda's efforts to manufacture 100 million doses annually within the decade. The vaccine has been approved in over 30 countries and has shown continued protection against dengue fever in long-term studies. [Extracted from the article]

A recent study conducted by researchers at the Royal Brompton and Harefield NHS Foundation Trust explores the safety of the yellow fever vaccine in adults with congenital heart disease (ACHD). As the population of ACHD patients continues to grow, more individuals are seeking to travel and work abroad, posing a unique challenge in terms of vaccination safety. The study highlights the potential lack of documentation of thymectomy on historic cardiac operation notes and its impact on the safety of the yellow fever vaccine for this patient group. Further information on this research can be found in the International Journal of Cardiology Congenital Heart Disease. [Extracted from the article]

A recent systematic review and meta-analysis conducted by researchers at Jackson State University evaluated the efficacy, immune response, and safety of dengue vaccines in children. The review analyzed 38 selected studies and found that dengue vaccines showed varying efficacy against all four serotypes of the virus. The CYD-TDV (Dengvaxia) and Tekade (TAK-003) vaccines showed strong protection against severe dengue, but their long-term efficacy varied. The vaccines triggered satisfactory immune responses, particularly in individuals previously exposed to dengue. The study concluded that dengue vaccines showed promising efficacy and immune response, especially against severe manifestations, but safety concerns require further investigation. [Extracted from the article]

Merck Sharp & Dohme LLC has been granted a patent for formulations of dengue virus vaccine compositions. The patent discusses the challenges in creating vaccines for dengue virus, which can cause a range of symptoms from mild illness to severe fever. Most vaccines tested are live attenuated vaccines, but non-replicating vaccine candidates are also being explored. The patent describes stable formulations for a live attenuated dengue vaccine, which include the addition of a cellulose derivative and a sugar alcohol or glycol to improve stability and yield after drying. These formulations aim to provide an effective and stable vaccine for preventing dengue virus infection. [Extracted from the article]

A patent application has been submitted for a method of viral inhibition by researchers from Australia. The application focuses on the treatment and prevention of flavivirus infections, particularly dengue fever, which is a significant arbovirus with millions of cases worldwide. Currently, there is no licensed vaccine or effective antiviral for dengue fever. The researchers have identified a retinoic acid analogue that shows efficacy in treating and preventing flavivirus infections, including dengue fever. The method involves administering the retinoic acid analogue to individuals in need of treatment or prevention. [Extracted from the article]

A new report from the Istituto Superiore per la Protezione e la Ricerca Ambientale in Italy provides data on African swine fever (ASF) and suggests strategies for optimizing vaccination against the disease. ASF is a severe suid disease that affects both the pig industry and wild suid populations. The researchers conducted a simulation study using data from wild boars in Lithuania to estimate the probability of successful ASF vaccination based on different eco-epidemiological factors. They found that a feeding site density of at least 1.0/km2 was necessary to achieve a vaccination rate of 75%. The study highlights the importance of considering wild boar movement patterns and ecological contexts when planning vaccination campaigns for ASF. [Extracted from the article]

Researchers from Fujian Normal University in China have published new data on the African Swine Fever Virus (ASFV). The study focuses on the development of a vaccine for ASF, a disease that causes high mortality in domestic pigs and wild boar. The researchers engineered a recombinant virus that effectively delivers proteins associated with ASFV, demonstrating good immunogenicity and safety. This vaccine candidate has the potential to provide highly effective protection against both ASFV and another related virus, pseudorabies. [Extracted from the article]

New research from Orient, New York, provides new data on African Swine Fever (ASF). The study re-evaluates the genotypes of ASF based on p72 sequences and proposes that the current 25 genotypes be reduced to only six. The researchers argue that the previous genotyping methods were not based on specific criteria and did not accurately compare with existing genotypes. They suggest using Arabic numerals instead of Roman numerals to differentiate between the new and old genotype classification systems. The study also discusses the usefulness of genotyping ASF based solely on the p72 gene sequence. [Extracted from the article]

A patent application has been submitted for a diagnostic test device that can detect anti-dengue virus antibodies. This device aims to identify individuals who have previously been infected with dengue and are seropositive, allowing them to be administered a dengue vaccine. The device uses dengue antigens conjugated to a detectable moiety to detect the presence of binding partners in a biological sample, indicating a dengue infection. The patent application provides detailed descriptions of the test device and its components, as well as the specific sequences and substitutions of the dengue antigens used. This invention could contribute to the prevention and management of dengue disease. [Extracted from the article]

A recent study conducted on yellow fever vaccination status found that there is a significant misclassification of vaccination status, both at the individual and country level. The study used a hierarchical Bayesian analysis and estimated the sensitivity and specificity of vaccination status. The median estimates for sensitivity and specificity across all countries were 0.69 and 0.70, respectively. The study suggests that reported vaccination coverage may be significantly underestimated in 10 out of 20 countries and significantly overestimated in 5 out of 20. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

A patent application has been filed for a new vaccine technology called "Live-Attenuated RNA Hybrid Vaccine Technology." This technology aims to address the manufacturing and safety issues associated with traditional live-attenuated vaccines. It involves using an artificial RNA delivery system to deliver replication-competent viral genomes, allowing for easy manufacturing and consistent safety. The technology has shown promise in developing vaccines against chikungunya virus and yellow fever virus, and has the potential to be used for other viruses like coronaviruses. [Extracted from the article]

Researchers at Nanjing Agricultural University have made advancements in understanding the African Swine Fever Virus (ASFV) through the mapping of a specific protein called pI215L using monoclonal antibodies. The ASFV is a significant pathogen that causes extensive damage to swine production globally. The study identified two novel B cell epitopes using the monoclonal antibodies, which could be used for further research on the function of pI215L and contribute to the development of serological diagnosis and vaccine research. The findings suggest that one of the monoclonal antibodies could be widely used in ASFV surveillance, while another could help distinguish different ASFV genotypes. [Extracted from the article]

Keywords: Arbovirus Infections; Bunyaviridae; Bunyaviridae Infections; Health and Medicine; Mosquito-Borne Diseases; Phlebovirus; RNA Virus Infections; RNA Viruses; Rift Valley Fever; Rift Valley Fever Virus; Risk and Prevention; Viral; Viral Hemorrhagic Fevers; Virology EN Arbovirus Infections Bunyaviridae Bunyaviridae Infections Health and Medicine Mosquito-Borne Diseases Phlebovirus RNA Virus Infections RNA Viruses Rift Valley Fever Rift Valley Fever Virus Risk and Prevention Viral Viral Hemorrhagic Fevers Virology 342 342 1 11/06/23 20231112 NES 231112 2023 NOV 8 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Current study results on Rift Valley fever have been published. Arbovirus Infections, Bunyaviridae, Bunyaviridae Infections, Health and Medicine, Mosquito-Borne Diseases, RNA Virus Infections, RNA Viruses, Rift Valley Fever, Rift Valley Fever Virus, Risk and Prevention, Viral, Viral Hemorrhagic Fevers, Virology, Phlebovirus Keywords for this news article include: First Affiliated Hospital of Shandong First Medical University, Jinan, People's Republic of China, Asia, Virology, Phlebovirus, RNA Viruses, Health and Medicine, Risk and Prevention, Arbovirus Infections, RNA Virus Infections, Bunyaviridae Infections, Mosquito-Borne Diseases, Rift Valley Fever Virus, Viral Hemorrhagic Fevers. [Extracted from the article]

Keywords: Hamilton; State:Montana; United States; North and Central America; Arbovirus Infections; Biological Products; Flaviviridae Infections; Flavivirus Infections; Health and Medicine; Immunization; Kyasanur Forest Disease; Kyasanur Forest Disease Virus; Public Health; RNA Virus Infections; RNA Viruses; Tick-Borne Diseases and Conditions; Vaccination; Vaccines; Viral; Viral Hemorrhagic Fevers; Virology EN Hamilton State:Montana United States North and Central America Arbovirus Infections Biological Products Flaviviridae Infections Flavivirus Infections Health and Medicine Immunization Kyasanur Forest Disease Kyasanur Forest Disease Virus Public Health RNA Virus Infections RNA Viruses Tick-Borne Diseases and Conditions Vaccination Vaccines Viral Viral Hemorrhagic Fevers Virology 257 257 1 11/06/23 20231112 NES 231112 2023 NOV 8 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Research findings on Tick-Borne Diseases and Conditions - Kyasanur Forest Disease are discussed in a new report. Hamilton, State:Montana, United States, North and Central America, Biological Products, Flaviviridae Infections, Flavivirus Infections, Arbovirus Infections, Health and Medicine, Immunization, Kyasanur Forest Disease Virus, Kyasanur Forest Disease, Public Health, RNA Virus Infections, RNA Viruses, Tick-Borne Diseases and Conditions, Vaccination, Vaccines, Viral, Viral Hemorrhagic Fevers, Virology Keywords for this news article include: Hamilton, Montana, United States, North and Central America, Arbovirus Infections, Biological Products, Flaviviridae Infections, Flavivirus Infections, Health and Medicine, Immunization, Kyasanur Forest Disease, Kyasanur Forest Disease Virus, Public Health, RNA Virus Infections, RNA Viruses, Tick-Borne Diseases and Conditions, Vaccination, Vaccines, Viral, Viral Hemorrhagic Fevers, Virology, National Institute of Allergy and Infectious Diseases (NIAID). [Extracted from the article]